You are visiting a website that is not intended for your region

The page or information you have requested is intended for an audience outside the United States. By continuing to browse you confirm that you are a non-US resident requesting access to this page or information. Switch to the US site. 

Venous Thromboembolism (VTE)

Understanding Venous Thromboembolism (VTE)

A common complication of prolonged immobility

Anyone can develop venous thromboembolism (VTE) regardless of age, gender or ethnicity. It is often the result of a prolonged period of immobility and can appear with little warning, with potentially life-threatening results.

Venous Thromboembolism (VTE)

A worldwide challenge for care environments.

VTE represents a serious and widespread clinical challenge:

  • There are 10 million cases of VTE reported worldwide every year 1 yet, VTE-related death is a largely undocumented, but preventable medical condition.
  • It is responsible for more deaths in Europe than breast cancer, prostate cancers, HIV AIDS and traffic accidents combined2.
  • Around 30% of patients will die within 30 days of VTE while 25% of unexpected inpatient deaths are diagnosed with PE at autopsy3.
  • Around 1/3 of patients with DVT develop post-thrombotic syndrome suffering swelling and pain3 and, for many (25%)4, the resultant chronic ulceration is associated with substantial on-going treatment costs5.
  • In the US, up to $19.1 billion is spent on treatment of long term complications every year following VTE.

VTE prevention

Ensure safe and effective VTE prevention for your patients. We offer a comprehensive range of VTE prevention pumps and garments that ensure you are able to provide safe and reliable VTE prevention for your most vulnerable patients.

Read more about our products


1. Jha AK, Larizgoitia I, Audera-Lopez C, Prasopa-Plaisier N, Waters H, Bates DW. The global burden of unsafe medical care: analytic modeling of observational studies. BMJ Qual Saf 2013; 22;809-15. Retrieved from:

2. Cohen AT, Agnelli A, Anderson FA et al. Venous thromboembolism (VTE) in Europe: The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007; 98: 756–764.

3. Beckman MG, Hooper WC, Critchley SE et al. Venous thromboembolism: a public health concern. Am J Prev Med. 2010; 38(4): S495-501 

4. Nelzen O, Bergqvist D, Lindhagen A. Leg ulcer etiology - a cross sectional population study. J Vasc Surg. 1991; 14: 557-64 cited in Nicolaides A, Fareed J, Kakkar A et al. Prevention and treatment of venous thromboembolism - International Consensus Statement. International Angiology. 2013; 32(2): 111-260

5. Ruppert A, Steinle T, Lees M. Economic burden of venous thromboembolism: a systematic review. J Med Econ. 2011; 14(1): 65-74

6. Mahan CE, Borrego ME, Woershing AL et al. Venous thromboembolism: Annualised United States model for total, hospital acquired and preventable costs utilising long-term attack rates. Thromb Haemost. 2012; 108(2): 291-302.